Recursion Pharmaceuticals (RXRX) Cash & Current Investments (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Cash & Current Investments data on file, last reported at $660.0 million in Q1 2026.

• Quarterly Cash & Current Investments rose 31.07% year-over-year to $660.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $660.0 million (up 31.07% YoY) and the FY2025 annual result came in at $747.9 million, up 25.19% from the prior year.
• Cash & Current Investments retreated to $660.0 million in Q1 2026, from $747.9 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $747.9 million in Q4 2025 to a low of $299.5 million in Q1 2024.
• A 5-year average of $502.7 million and a median of $476.1 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 132.47% — and 2024, when it slumped 36.87%.
• Tracing RXRX's Cash & Current Investments over 5 years: stood at $551.2 million in 2022, then dropped by 28.37% to $394.8 million in 2023, then jumped by 51.32% to $597.4 million in 2024, then advanced by 25.19% to $747.9 million in 2025, then retreated by 11.75% to $660.0 million in 2026.
• The last three Cash & Current Investments figures came in at $660.0 million (Q1 2026), $747.9 million (Q4 2025), and $663.0 million (Q3 2025), per Business Quant data.